CN106237317A - 由结核分枝杆菌抗原组成的结核疫苗 - Google Patents

由结核分枝杆菌抗原组成的结核疫苗 Download PDF

Info

Publication number
CN106237317A
CN106237317A CN201510324548.6A CN201510324548A CN106237317A CN 106237317 A CN106237317 A CN 106237317A CN 201510324548 A CN201510324548 A CN 201510324548A CN 106237317 A CN106237317 A CN 106237317A
Authority
CN
China
Prior art keywords
tuberculosis
mycobacterium
sequence
vaccine
rv0792c
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510324548.6A
Other languages
English (en)
Chinese (zh)
Inventor
刘军
张鹭
郭沛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHENGDU YONG'AN PHARMACEUTICAL Co Ltd
Fudan University
Original Assignee
CHENGDU YONG'AN PHARMACEUTICAL Co Ltd
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHENGDU YONG'AN PHARMACEUTICAL Co Ltd, Fudan University filed Critical CHENGDU YONG'AN PHARMACEUTICAL Co Ltd
Priority to CN201510324548.6A priority Critical patent/CN106237317A/zh
Priority to PCT/CN2015/091068 priority patent/WO2016201825A1/fr
Priority to CN201580079653.6A priority patent/CN107531764A/zh
Publication of CN106237317A publication Critical patent/CN106237317A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201510324548.6A 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗 Pending CN106237317A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201510324548.6A CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗
PCT/CN2015/091068 WO2016201825A1 (fr) 2015-06-15 2015-09-29 Antigènes de mycobacterium tuberculosis et leurs applications
CN201580079653.6A CN107531764A (zh) 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510324548.6A CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗

Publications (1)

Publication Number Publication Date
CN106237317A true CN106237317A (zh) 2016-12-21

Family

ID=57546635

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201510324548.6A Pending CN106237317A (zh) 2015-06-15 2015-06-15 由结核分枝杆菌抗原组成的结核疫苗
CN201580079653.6A Pending CN107531764A (zh) 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580079653.6A Pending CN107531764A (zh) 2015-06-15 2015-09-29 结核分枝杆菌抗原及其应用

Country Status (2)

Country Link
CN (2) CN106237317A (fr)
WO (1) WO2016201825A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506108A (zh) * 2017-04-07 2019-11-26 成都永安制药有限公司 过表达phoP-phoR的重组BCG
CN110590958A (zh) * 2019-09-11 2019-12-20 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN111655281A (zh) * 2018-01-26 2020-09-11 加利福尼亚大学董事会 用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送
CN115125276A (zh) * 2022-06-24 2022-09-30 天津大学青岛海洋技术研究院 枯草芽孢杆菌中三酰基甘油的合成方法与应用
CN116003540A (zh) * 2022-12-08 2023-04-25 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原组合物pfhp010的制备及其应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114272364B (zh) * 2021-12-22 2024-06-18 中国人民解放军总医院第八医学中心 一种结核分枝杆菌串联dna疫苗w541及其制备方法与应用
CN116041541B (zh) * 2022-11-30 2024-03-15 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原eppa011及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504523A (ja) * 2001-06-22 2005-02-17 ヘルス プロテクション エージェンシー 低酸素圧下で発現するマイコバクテリア抗原
CN1342771A (zh) * 2001-09-17 2002-04-03 复旦大学 结核分枝杆菌Ag85B抗原的表达纯化和作为疫苗组份的应用
ITRM20030411A1 (it) * 2003-08-29 2005-02-28 Consiglio Nazionale Ricerche Uso di sequenze geniche specifiche di mycobacterium tubercolosis ecorrispondenti proteine per la diagnosi e la prevenzione di infezione tubercolare.
US8361482B2 (en) * 2007-11-27 2013-01-29 Aeras Global Tb Vaccine Foundation Recombinant BCG tuberculosis vaccine designed to elicit immune responses to mycobacterium tuberculosis in all physiological stages of infection and disease
GB0918154D0 (en) * 2009-10-16 2009-12-02 Isis Innovation Mycobacterial vaccines
CN102260328B (zh) * 2010-07-15 2013-09-25 华中农业大学 结核分枝杆菌的抗原蛋白及应用
CN102161695A (zh) * 2011-03-08 2011-08-24 复旦大学 一种用于耐药结核血清学诊断的Rv1793重组蛋白
US10703784B2 (en) * 2011-09-30 2020-07-07 La Jolla Institute For Allergy And Immunology Antigens and epitopes derived from Mycobacterium tuberculosis
CN103304646B (zh) * 2012-03-09 2015-02-25 中国医学科学院病原生物学研究所 结核分枝杆菌候选抗原多肽及其应用
CN104292315A (zh) * 2014-10-27 2015-01-21 武汉大学 一种Rv2645蛋白的制备及其在结核诊断与重组BCG疫苗中的应用

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110506108A (zh) * 2017-04-07 2019-11-26 成都永安制药有限公司 过表达phoP-phoR的重组BCG
CN110506108B (zh) * 2017-04-07 2023-10-24 成都安永鼎业生物技术有限公司 过表达phoP-phoR的重组BCG
CN111655281A (zh) * 2018-01-26 2020-09-11 加利福尼亚大学董事会 用于结核病的含环二核苷酸佐剂的疫苗的鼻内递送
CN110590958A (zh) * 2019-09-11 2019-12-20 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN110590958B (zh) * 2019-09-11 2021-04-13 中国人民解放军总医院第八医学中心 一种串联多肽及其在抗结核分枝杆菌的免疫保护中的应用
CN115125276A (zh) * 2022-06-24 2022-09-30 天津大学青岛海洋技术研究院 枯草芽孢杆菌中三酰基甘油的合成方法与应用
CN116003540A (zh) * 2022-12-08 2023-04-25 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原组合物pfhp010的制备及其应用
CN116003540B (zh) * 2022-12-08 2024-04-16 中国疾病预防控制中心传染病预防控制所 一种结核分枝杆菌抗原组合物pfhp010的制备及其应用

Also Published As

Publication number Publication date
WO2016201825A1 (fr) 2016-12-22
CN107531764A (zh) 2018-01-02

Similar Documents

Publication Publication Date Title
CN106237317A (zh) 由结核分枝杆菌抗原组成的结核疫苗
Delogu et al. Comparative immune response to PE and PE_PGRS antigens of Mycobacterium tuberculosis
Brodin et al. ESAT-6 proteins: protective antigens and virulence factors?
Demangel et al. Differential effects of prior exposure to environmental mycobacteria on vaccination with Mycobacterium bovis BCG or a recombinant BCG strain expressing RD1 antigens
Tanghe et al. Protective efficacy of a DNA vaccine encoding antigen 85A from Mycobacterium bovis BCG against Buruli ulcer
CN102836425B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
US8747866B2 (en) Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti
US8173773B2 (en) Mycobacterium tuberculosis fusion protein and uses thereof
Twine et al. BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses
CN110506108B (zh) 过表达phoP-phoR的重组BCG
Romano et al. Immunogenicity and protective efficacy of tuberculosis subunit vaccines expressing PPE44 (Rv2770c)
Teimourpour et al. Construction of a DNA vaccine encoding Mtb32C and HBHA genes of Mycobacterium tuberculosis
CN102439134B (zh) 包含过表达PhoP和/或PhoP调节子蛋白的重组BCG菌株的结核疫苗
Fan et al. Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model
Festjens et al. SapM mutation to improve the BCG vaccine: Genomic, transcriptomic and preclinical safety characterization
Kim et al. Immunogenicity and vaccine potential of InsB, an ESAT-6-like antigen identified in the highly virulent Mycobacterium tuberculosis Beijing K strain
Xiang et al. Immunogenicity and protective efficacy of a fusion protein tuberculosis vaccine combining five Esx family proteins
Roupie et al. Immunogenicity and protective efficacy of DNA vaccines encoding MAP0586c and MAP4308c of Mycobacterium avium subsp. paratuberculosis secretome
Rashidian et al. Designing and construction of a DNA vaccine encoding tb10. 4 gene of Mycobacterium tuberculosis
Mulongo et al. Cattle immunized against the pathogenic L-α-glycerol-3-phosphate oxidase of Mycoplasma mycoides subs. mycoides fail to generate neutralizing antibodies and succumb to disease on challenge
Grover et al. Expression and purification of the Mycobacterium tuberculosis complex-restricted antigen CFP21 to study its immunoprophylactic potential in mouse model
Wu et al. Latent tuberculosis infection amongst new recruits to the Chinese army: comparison of ELISPOT assay and tuberculin skin test
CN107530414B (zh) 区分活动性结核病和潜伏结核感染的结核分枝杆菌抗原及其应用
CN101248084B (zh) 包含潜伏感染阶段期间所表达的抗原的结核疫苗
JP5994127B2 (ja) 新規な組換えｂｃｇワクチン

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161221